Brain Metastases: Q&A
1. What are the early symptoms of brain metastases?
Symptoms of brain metastases depend on the number and location of the tumors; common symptoms include headache, nausea and vomiting, seizures, and limb weakness or numbness.Cognitive impairment, speech difficulties, and visual changes may also occur.
2. Which cancers are prone to brain metastasis?
Lung cancer is the cancer most prone to brain metastasis; approximately 40% of lung cancer patients eventually develop brain metastases.Breast cancer, melanoma, colorectal cancer, and renal cell carcinoma are also common causes.
3. What are the surgical treatment options for brain metastases?
Surgical resection may be considered for solitary, large, or symptomatic brain metastases to alleviate mass effect and intracranial hypertension.For multiple metastases, resection of the most symptomatic lesion may be chosen.
4. What is minimally invasive treatment for brain metastases?
Stereotactic radiotherapy, such as Gamma Knife, is a primary minimally invasive treatment for brain metastases; it delivers a single, high-dose, precise radiation beam to the tumor without the need for craniotomy.It is suitable for 1–4 small metastatic lesions.
5. What targeted therapies and immunotherapies are available for brain metastases?
Targeted drugs directed at the primary cancer can be effective against some brain metastases—for example, EGFR inhibitors used for brain metastases from lung cancer.
6. How can patients with brain metastases manage their symptoms?
Glucocorticoids can alleviate cerebral edema, headaches, and neurological symptoms.Antiepileptic drugs control seizures.Dehydrating agents lower intracranial pressure.Analgesic therapy is required for patients with significant headaches.
7. Prognosis and follow-up for patients with brain metastases?
The prognosis for brain metastases depends on the primary cancer type, the number of metastatic lesions, the control of systemic disease, and the patient's physical condition.Regular MRI follow-ups are used to monitor changes in intracranial lesions.
